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Translocation of Non-Canonical 
Polypeptides into Cells Using 
Protective Antigen
Amy E. Rabideau*, Xiaoli Liao*, Gizem Akçay & Bradley L. Pentelute
A variety of pathogenic bacteria infect host eukaryotic cells using protein toxins, which enter the 
cytosol and exert their cytotoxic effects. Anthrax lethal toxin, for example, utilizes the membrane-
spanning translocase, protective antigen (PA) pore, to deliver the protein toxin lethal factor 
(LF) from the endosome into the cytosol of cells. Previous work has investigated the delivery of 
natural peptides and enzymatic domains appended to the C-terminus of the PA-binding domain 
of lethal factor (LFN) into the cytosol via PA pore. Here, we move beyond natural amino acids and 
systematically investigate the translocation of polypeptide cargo containing non-canonical amino 
acids and functionalities through PA pore. Our results indicate translocation is not perturbed with 
alterations to the peptide backbone or side-chain. Moreover, despite their structural complexity, we 
found that the small molecule drugs, doxorubicin and monomethyl auristatin F (MMAF) translocated 
efficiently through PA pore. However, we found cyclic peptides and the small molecule drug 
docetaxel abrogated translocation due to their large size and structural rigidity. For cargos that 
reached the cytosol, we demonstrated that each remained intact after translocation. These studies 
show PA is capable of translocating non-canonical cargo provided it is in a conformational state 
conducive for passage through the narrow pore.
Nature has evolved several types of translocation systems for delivery of toxic proteins into host cells1. 
Certain pathogenic bacteria such as Vibrio cholerae, Corynebacterium diphtheria, and Bacillis anthracis 
infect host cells with cholera, diphtheria, and anthrax toxin, respectively2. These protein toxins access 
the cytosol by two main pathways: transport through a translocase from the host cell endosome or ret-
rograde endocytosis from the endosome to the Golgi and endoplasmic reticulum2. Anthrax toxin is one 
example that utilizes a translocase to deliver protein toxins from the endosome into the cell cytosol3.
Anthrax lethal toxin is comprised of two proteins, protective antigen (PA) and lethal factor (LF)3. The 
pore-forming protein, PA83 binds to an anthrax toxin receptor on the host cell surface and is then prote-
olytically activated by furin protease to give PA634, triggering oligomerization of PA63 into a heptameric5 
or octameric6 pre-pore. LF binds to the pre-pore through the 263-residue N-terminal domain (LFN) 
with nanomolar affinity7. Up to three8 or four6 molecules of LF can bind to the heptameric or octameric 
pre-pore, respectively. The entire complex is then endocytosed and the low pH triggers a conformational 
rearrangement of the pre-pore to form a pore that spans through the endosomal membrane9, initiating 
translocation of LF into the cytosol10,11.
Biophysical and biochemical experiments of LF translocation through the cation-selective PA pore have 
elucidated the translocation mechanism into the cell cytosol12,13. The working model points toward a num-
ber of key factors that govern translocation through PA pore and subsequent escape from the endosome:
•	 PA pre-pore undergoes conformational rearrangement to form a pore in the endosomal membrane5,14.
•	 Charge state-dependent Brownian ratchet drives translocation through the PA pore12.
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•	 Protein cargo partially unfolds in the acidic endosome prior to translocation15,16.
•	 Cargo passes through the PA conduit of approximately 12 Å diameter13,17.
Taking advantage of these drivers of translocation, researchers have investigated the delivery of various 
protein cargos fused to the C-terminus to LFN through PA pore. Enzymes or enzymatic domains such 
as β -lactamase18,19, Pseudomonas exotoxin A, Diphtheria toxin A chain20,21, actin cross-linking domain 
from the Vibrio cholerae RTX toxin22, Shiga toxin23, and Legionella pneumophila flagellin protein24 as 
well as antibody mimic proteins25 have been delivered into cells using the PA/LFN system. These studies 
showed that the PA pore is efficient in transporting naturally occurring or recombinantly expressed 
proteins. However, the question of whether PA pore can accommodate and transport molecules beyond 
natural polypeptides has yet to be investigated. One example has shown the effects on translocation 
when D-amino acids and cysteic acid are incorporated at the N-terminus of LFN26. Recently, Rabideau, 
et al. demonstrated that mirror image polypeptides and proteins27 on the C-terminus of LFN can trans-
locate efficiently through PA pore. Some non-natural molecules, including small molecule drugs and 
polypeptides with backbone or side chain modifications, have attracted research interest because of their 
potential as therapeutics. Investigating the translocation of these non-canonical polypeptides would not 
only aid in their cytosolic delivery, but also provide insight into the mechanism and promiscuity of the 
PA translocase.
In the present study, we investigated the translocation of various non-canonical polypeptide moie-
ties through the PA translocase (Fig. 1a). We designed our experiments to seek answers to three ques-
tions: 1, Do non-natural amino acids affect translocation through PA pore? 2, Can PA pore still tolerate 
cargos containing non-natural peptide backbones? 3, Can a constrained polypeptide or rigid natural 
product pass through the 12 Å pore? To carry out these investigations, we leveraged the use of sortase 
A (SrtA)-mediated ligation. The non-canonical polypeptide cargos were synthesized with an N-terminal 
oligoglycine motif and attached to the C-terminus of LFN-DTA using the LPXTG tag and SrtA28 to give 
LDn constructs (Fig. 1b). DTA (A chain of diphtheria toxin) serves as a reporter of translocation since 
Figure 1. Delivery of non-canonical polypeptide cargo into the cytosol a) Non-canonical polypeptide 
cargo (green star) ligated to the C-terminus of LFN (pdb: 1J7N) to translocate through PA pore (pdb: 3J9C) 
b) Sortase A-mediated ligation of LFN-DTA-LPSTGG and G5-cargo to form constructs are comprised of 
LFN-DTA and non-canonical polypeptide cargo (LDn).
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it inhibits protein synthesis upon entry into the cytosol5,23,29. From our investigations, we found peptides 
containing minor modifications to the backbone or amino acid side chains, peptidomimetic monome-
thyl auristatin F (MMAF), and the small molecule drug, doxorubicin translocate efficiently. In contrast, 
cyclic peptides and the small molecule drug, docetaxel caused disruption to the translocation process. 
Our findings support the hypothesis that the chemical composition of the cargo does not inhibit the 
Brownian ratchet provided the cargo is able to adopt a conformational state in which it can pass through 
the narrow pore.
Results
Translocation of non-canonical polypeptide cargos with backbone or side chain modifica-
tions. We first investigated the translocation of peptides containing either backbone or side chain 
modifications. We chose β -alanine and N-methyl-alanine for backbone modifications, and propargylg-
lycine and 2,4,5-tri fluoro-phenylalanine for side chain modifications. These modifications were incor-
porated into a model peptide containing all natural amino acids, G5-AKFRPDSNVRG (Supplementary 
Table 1). These peptides were sortagged onto LFN-DTA to give LDn1–5 (Fig.  2a; Supplementary Table 
2). We first used a protein synthesis inhibition assay to analyze translocation efficiency of each con-
struct5,23,29. For this assay, ten-fold serial dilutions of each purified conjugate were added to CHO-K1 
cells in the presence of 20 nM PA and incubated for 30 minutes. Cells were washed three times with PBS 
then incubated with medium supplemented with 3H-Leu for 1 h. After incubation, medium was removed, 
cells were washed, and 3H-Leu incorporation was measured by a scintillation counter to determine the 
translocation efficiency of each cargo. According to Fig. 2b, each non-canonical cargo (LDn2–5) trans-
located as efficiently as the controls (Supplementary Table 3), LFN-DTA and LDn1, indicating that these 
peptides, which contain backbone and side chain modifications can be appended to the C-terminus of 
LFN-DTA without major interference to the translocation process.
We further analyzed the cytosolic presence of the non-canonical peptide conjugates using digitonin 
extraction and western blot. CHO-K1 cells were treated with 100 nM LDn1–5 in the presence of 20 nM 
PA for 12 hours to allow for multiple rounds of endocytosis and translocation. After trypsin digestion of 
surface bound materials and washing with PBS, the cytosolic proteins were extracted using a lysis buffer 
containing 50 μ g mL−1 digitonin, a mild detergent used to permeabilize only the plasma membrane30. 
The proteins extracted by digitonin were analyzed by western blot immunostained with anti-Erk1/2 (a 
cytosolic marker) and anti-Rab5 (an early endosome marker) to confirm the presence of only cytosolic 
proteins. Using immunostaining by anti-DTA antibody, we observed bands corresponding to LDn2, 4, 
and 5 with intensities similar to that of LDn1 (Fig. 2c). We also analyzed the total cell lysate using a buffer 
containing 1% NP-40 and observed comparable band intensities detected by the anti-DTA antibody 
(Supplementary Figure 1). This data further confirmed the results from the protein synthesis inhibition 
assay, indicating that these non-natural modifications did not interfere with the translocation through PA 
pore. In addition, we performed control experiments with LDn2 by incubating the cells at 4 °C instead 
of 37 °C, incubating with an inhibitor of endosomal acidification (Bafilomycin A1), or using a mutant 
PA (PA[F427H]) that binds LFN but arrests translocation. In all three cases, we observed no band cor-
responding to LDn2, indicating the translocation process followed the same mechanism as LFN-DTA, 
which requires active endocytosis, an acidic endosome, and a functional PA (Fig. 2c).
Translocation of cyclic peptides. We expanded our library of non-canonical peptides under investi-
gation to include cyclic peptides. In comparison to linear peptides, cyclic peptides have increased struc-
tural rigidity and proteolytic stability, making them attractive therapeutic candidates31. We cyclized L 
and D forms of the model peptide (1) using native chemical ligation (Fig.  3a). As demonstrated in 
Supplementary Scheme 1, we installed a Cys residue on the ε -amino group of the Lys residue of the 
peptide thioester in both L (7) and D (8) forms. The L model peptide containing an alkylated Cys residue 
at the Lys position served as a linear control (6) for the translocation of the cyclic peptides. Each peptide 
was sortagged onto LFN-DTA then analyzed using both the protein synthesis inhibition and western blot 
assays. We found that there was a substantial reduction in translocation efficiency for both LDn7 and 
LDn8, as compared to LFN-DTA and LDn6 (Fig. 3b; Supplementary Table 3). Furthermore, we treated 
CHO-K1 with 100 nM LDn6–8 in the presence of 20 nM PA overnight then analyzed cytosolic delivery 
in digitonin extracted materials. The western blot immunostained with anti-DTA showed no detectable 
band for LDn7 and LDn8, while the linear control peptides LDn1 and LDn6 showed similar band inten-
sity (Fig. 3c). A small amount of LDn7 and LDn8 was detected in the total cell lysate (Supplementary 
Figure 2), indicating some cargos were trapped in endosomes. The western blot result was consistent with 
the protein synthesis assay results, showing that translocation was substantially reduced for the cyclic 
peptide conjugates, LDn7 and LDn8, compared to the linear peptide controls.
Translocation of complex small molecules. We next investigated the ability of PA to translocate 
complex, cytotoxic small molecules that are frequently used in antibody-drug conjugates: doxorubicin, 
docetaxel, and monomethyl auristatin F (MMAF)32. Direct translocation of these small molecules into 
the cytosol would be of great interest for the delivery of impermeable chemotherapeutics or other 
small molecule drugs. These small molecules were conjugated through the Cys residue of the peptide, 
G5-LRRLRAC, using a maleimide functional group (Fig. 4a; Supplementary Scheme 2). The peptide-small 
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molecule products were then sortagged onto LFN-DTA (LDn9–11, respectively) for investigation of 
translocation through PA pore. Again, we used the protein synthesis inhibition assay and found that 
LDn9 and LDn11 translocated as efficiently as the LFN-DTA control, while translocation was completely 
arrested for LDn10 (Fig. 4b; Supplementary Table 3). We then treated the cells with 100 nM LDn9–11 in 
the presence of 20 nM PA overnight and analyzed cytosolic delivery by immunostaining with anti-DTA 
antibody. We observed similar band intensities for LDn9 and LDn11 as compared to LFN-DTA, while 
no band was detectable for LDn10 (Fig. 4c). We also analyzed the total cell lysate and observed compa-
rable band intensities with the anti-DTA antibody (Supplementary Figure 2). The western blot results 
were consistent with protein synthesis inhibition results, which suggest that the PA pore was efficient 
in accommodating cytotoxic molecules whose structures were either similar to (i.e. MMAF) or distinct 
from (i.e. doxorubicin) polypeptides. We hypothesized that the three-dimensional size of the molecule 
Figure 2. Translocation of non-canonical peptides a) Peptides 1–5 containing non-canonical side-chain 
modifications were ligated to LFN-DTA using SrtA to form LDn1–5 b) Protein synthesis inhibition assay 
in CHO-K1. Ten-fold serial dilutions of LDn1–5 and LFN-DTA were added to CHO-K1 in the presence 
of 20 nM PA and incubated for 30 minutes at 37 °C and 5% CO2 then washed with PBS. Treated cells were 
chased with 3H-Leu in Leu-free medium for 1 hour then washed and read using a scintillation counter. c) 
CHO-K1 cells were treated with 100 nM LDn’s in the presence of 20 nM PA for 12 hours. The cells were 
lifted and the cell surface was trypsin digested for 5 minutes then subsequently washed with PBS. The cell 
cytosol was extracted using 50 μ g mL−1 digitonin for 10 min on ice. The cytosol extraction was analyzed by 
western blot. The following controls were also analyzed: incubation at 4 °C (instead of 37 °C), incubation 
with Bafilomycin A1, and use of mutant PA, PA[F427H]. Cropped blots are used in western blot data (c).
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was a major factor that contributed to translocation efficiency. Therefore, we estimated the longest linear 
distance for doxorubicin and docetaxel based on published crystal structures. Despite different possible 
conformational arrangements, we found that the longest linear distance for doxorubicin in the crystal 
structure to be about 10.3 Å33, while that of docetaxel was about 13.5 Å34, which is close to the estimated 
PA pore size (12 Å)17. Taken together, these data suggested that PA pore was promiscuous enough to 
translocate cytotoxic small molecules, but with a size limitation due to the inherent size of the pore.
Figure 3. Translocation of cyclic peptides a) Linear control peptide and L and D cyclic peptides to form 
LDn6–8, respectively b) CHO-K1 were treated with ten-fold serial dilutions of LDn6–8 and LFN-DTA in the 
presence of 20 nM PA for 30 minutes. The same experimental conditions were used as previously described. 
c) CHO-K1 were treated with 100 nM LD6–8 in the presence of 20 nM PA for 12 hours then subjected to 
cytosolic extraction for western blot, as previously described. Cropped blots are used in western blot data (c).
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Figure 4. Translocation of small molecules a) Small molecules doxorubicin, docetaxel, and monomethyl 
auristatin F (MMAF) were conjugated at the cysteine residue of G5-LRRLRAC then ligated to LFN-DTA 
to form LDn9–11. b) CHO-K1 cells were treated with ten-fold serial dilutions of LDn9–11 and LFN-DTA 
in the presence of 20 nM PA for 30 minutes. The same experimental conditions were used as previously 
described. c) CHO-K1 cells were treated with 100 nM LDn9–11 in the presence of 20 nM PA for 12 hours 
then digitonin extracted and run on western blot, as previously described. Cropped blots are used in western 
blot data (c).
Translocation of intact cargo. Our studies indicate a variety of non-canonical polypeptide cargo 
can translocate through PA pore into the cell cytosol. To verify that the protein conjugates containing 
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non-canonical polypeptide cargos passed through the pore and into the cytosol without any truncations, 
we analyzed the translocation of intact cargos. For this analysis, we installed a biotin at the C-terminus 
of each non-canonical polypeptide cargo that translocated efficiently (Fig. 5a,b). The C-terminal biotin 
provided a small tag for western blot detection of intact cargos, which were sortagged onto LFN-DTA as 
previously described (LDn1-bio to LDn6-bio, LDn9-bio, and LDn11-bio). Translocation of the biotiny-
lated conjugates was achieved by treating CHO-K1 cells with 100 nM LDn1-bio to LDn6-bio, LDn9-bio, 
and LDn11-bio in the presence of 20 nM PA for 12 hours. The cells were subjected to the same harvest 
and digitonin lysis conditions as previously described. Prior to western blot analysis, the SDS-PAGE 
gel was run for approximately twice as long as the previous experiments in order to differentiate the 
shifts in molecular weights of the conjugates containing intact cargo. The western blot in Fig.  5c was 
stained with anti-DTA (subsequently stained with goat anti-mouse IRdye 800CW secondary antibody) 
and streptavidin IRdye 680LT. The co-staining of anti-DTA and streptavidin for all the biotinylated con-
jugates (LDn1-bio to LDn6-bio, LDn9-bio, and LDn11-bio) confirmed the presence of the intact protein 
conjugates in the cytosol of cells. Since doxorubicin and MMAF were conjugated through non-amide 
linkages (i.e. maleimide) we relied on shifts in molecular weight in the western blot to confirm that 
the conjugates remained intact after translocation. As demonstrated in Fig.  5c, the shifts in molecular 
weight for the biotinylated conjugates corresponded with the 1 ng loading controls (LFN-DTA, LDn1-bio, 
LDn11-bio) as well as the non-biotinylated translocated materials (LDn2, LDn9, and LDn11) indicating 
that the translocated material was indeed intact.
Discussion
In this paper, we investigated whether PA pore could efficiently transport non-canonical polypeptides 
into the cell cytosol. We used two separate assays to evaluate translocation efficiency. The protein synthe-
sis inhibition assay based on DTA activity is widely used in the anthrax toxin field to probe translocation, 
Figure 5. Translocation of C-terminally biotinylated cargo a) Non-canonical peptides 1–6 were modified 
to contain biotin on a C-terminal lysine residue (1-bio to 6-bio) then ligated to LFN-DTA to form LDn1-bio 
to 6-bio b) Peptides containing the small molecules, doxorubicin and monomethyl auristatin F (MMAF) 
were modified to contain biotin on a C-terminal lysine residue (9-bio and 11-bio, respectively) then ligated 
to LFN-DTA to form LDn9-bio and LDn11-bio c) CHO-K1 cells were treated with 100 nM LDn2, LDn9, 
LDn11, LDn1-bio to LDn6-bio, LDn9-bio, and LDn11-bio in the presence of 20 nM PA for 12 hours then 
digitonin extracted and run on western blot, as previously described. Cropped blots are used in western blot 
data (c).
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enabling direct comparison to the previous reports. We also used cytosolic extraction by digitonin and 
western blot analysis to further investigate delivery of the cargos in the cytosol.
Based on these two assays, we found that several variants did not perturb translocation through PA pore. 
These peptides contain backbone modifications, or side chain modifications that can be used to increase 
proteolytic stability (e.g. β -alanine, N-methyl-alanine), binding affinity (e.g. fluoro-phenylalanine), or 
serve as chemical handles (e.g. alkyne or biotin groups) for follow-up analysis. We also demonstrated 
the translocation of small molecule drugs such as doxorubicin and MMAF through PA pore. Altogether 
these examples indicate that PA pore is relatively promiscuous in terms of the substrates that can be 
translocated. Once unfolding and translocation is initiated by the interaction of LFN with PA pore in the 
acidic endosome, the pore is able to accommodate the trailing segment, with high tolerance for chemical 
modifications.
The digitonin extraction and western blot analysis not only confirmed the cytosolic delivery of these 
materials through PA pore, but also supported the reported translocation mechanism. The requirement 
of endocytosis, endosome acidification, and active PA pore was indicated by the control experiments 
where no bands were detected using 4 °C, Bafilomycin A1, or PA [F427H].
Model cyclic peptides and complex small molecules such as docetaxel perturbed translocation 
through PA pore, as indicated by the substantial reduction or abolishment of protein synthesis inhibi-
tion. We hypothesize that the size of the molecules were responsible for arresting translocation. For the 
cyclic peptides, although the structures are unknown, the potential rigidity and large size could perturb 
translocation. Furthermore, inhibited translocation is independent of stereochemistry, as evidenced by 
the translocation of the D cyclic peptide cargo. Although there was some detectable protein synthesis 
inhibition activity with the cyclic peptides, we observed no material by western blot of the cytosolic 
fractions. We note that the protein synthesis inhibition assay is a more sensitive assay since its readout is 
correlated with the activity of the DTA enzyme, which turns over at very low concentrations, while the 
western blot approach does not allow us to detect very low levels of protein. Regardless of the detection 
methods, both demonstrated that these large and constrained cargos had difficulty passing through PA 
pore. These results provide additional evidence to support the translocation mechanism, where cargos 
need to be in an extended confirmation to pass through the pore; large and rigid molecules cannot effi-
ciently pass through the pore. This result also provides design principles for different cargos of interest.
Moreover, we analyzed the translocation of intact polypeptide cargo. Non-canonical polypeptide 
cargo, which were found to translocate efficiently were biotinylated on the C-terminus. After transloca-
tion and digitonin extraction, the western blot was analyzed for the presence of DTA as well as biotin 
using streptavidin labeled with an IRdye. Co-staining of DTA and streptavidin for each conjugate as 
well as band shifts corresponding to the correct molecular weights indicated that the protein conjugates 
containing non-canonical polypeptide cargos remained intact after translocation through PA pore into 
the cytosol.
Nature evolved to utilize 20 amino acids to make up proteins. Recently, there has been great interest 
to incorporate non-canonical amino acids into polypeptides in order to enhance biological properties or 
to study biological processes. For our study, we asked the basic question of whether these non-natural 
amino acids could be efficiently translocated into the cell cytosol through the anthrax toxin PA pore. 
Indeed, we found the PA translocase still functions despite the presence of non-canonical cargo.
Methods
Peptide synthesis. Select peptides were synthesized under fast-flow coupling/deprotection condi-
tions using Fmoc chemistry protocols for SPPS35. All the peptides were synthesized on aminomethyl 
resin with the rink amide linker at a 0.1 mmol scale. After synthesis, peptides were cleaved and side 
chain protecting groups were removed by TFA cleavage. A typical TFA cleavage solution contained TFA/
H2O/EDT/TIPS (94/2.5/2.5/1 v/v). Resin was treated with TFA cleavage solution for 2 hours at room 
temperature, followed by N2 bubbling until dryness. The crude peptide was recovered by precipitation 
with cold ethyl ether as a white powder, then dissolved in 50% aqueous acetonitrile containing 0.1% TFA 
and lyophilized.
LCMS analysis. The purity of all peptides and proteins were analyzed by high resolution LC-MS 
(Agilent 6520 Accurate-Mass quadrupole time-of-flight liquid chromatography mass spectrometry sys-
tem). The samples were analyzed on an Agilent Zorbax 300SB C3 column (2.1 × 150 mm, 5 μ m) using 
0.8 mL min−1 and a linear gradient of 1–61% or 5–65% B’ over 9 min (A’: water + 0.1% formic acid; B’: 
acetonitrile + 0.1% formic acid). The observed mass was reported by averaging the major peak in the 
total ion current (TIC). For each protein, the charge state series was deconvoluted (maximum entropy 
setting) using Agilent MassHunter Bioconfirm.
Preparative, semi-preparative, and analytical RP-HPLC. Crude peptides were purified by reverse 
phase-HPLC. The peptides were dissolved in 99:1 or 95:5 A:B (A: water + 0.1% TFA; B: acetonitrile + 
0.1% TFA) and 6 M guanidine hydrochloride was added depending on the solubility of the peptide. For 
preparative RP-HPLC purification, we used an Agilent Zorbax SB C18 column (21.2 × 250 mm, 7 μ m) at a 
flow rate of 10 mL min−1 at 1–41% or 5–45% B over 80 min. For semi-preparative RP-HPLC purification, 
we used an Agilent Zorbax SB C18 column (9.4 × 250 mm, 5 μ m) at a flow rate of 5 mL/min over the same 
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gradient. UV absorbance was monitored at 214 nm. Purity of the fractions was analyzed by MALDI or 
LC-MS. HPLC fractions from preparative or semi-preparative HPLC were spotted with MALDI matrix 
alpha-cyano-4-hydroxycinnamic acid (CHCA) in 50% A: 50% B and checked for the correct molecular 
masses. The analytical RP-HPLC Agilent C18 Zorbax SB column (2.1 × 150 mm, 5 μ m) was used to con-
firm the purity of fractions at a flow rate of 0.5 mL/min over a linear gradient of 1–51% B over 12 min. 
Analytical HPLC UV absorbance traces were measured at 214 nm.
Conjugation of docetaxel, doxorubicin, and MMAF to G5-LRRLRAC. Doxorubicin-maleimide 
(16 mg) or docetaxel-maleimide (30 mg) was added to a 16.5 mM solution of peptide G5-LRRLRAC in DMF 
to a final concentration of 16.5 mM (1:1). The reaction mixtures were allowed to stir at 36 °C for 5 hours, 
followed by additional 10 hours at room temperature, at which time LCMS analysis indicated consump-
tion of the starting peptide and formation of G5-LRRLRAC(doxorubicin) and G5-LRRLRAC(docetaxel) 
peptide conjugates. The products were purified by semi-preparative RP-HPLC to give 35 mg (82% yield) 
of G5-LRRLRAC(doxorubicin) and 50 mg (75% yield) of G5-LRRLRAC(docetaxel).
MMAF was also ligated to G5-LRRLRAC using 2 mg maleimide-MMAF (20 mM) in DMSO and 
20 mM G5-LRRLRAC (2.5 mg). Reaction was incubated at room temperature for 2 h. LCMS indicated 
consumption of the peptide starting material and formation of G5-LRRLRAC(MMAF) product. The 
product was purified by semi-preparative RP-HPLC to give 4.8 mg (86% yield).
Similar coupling strategies were utilized for the synthesis of G5-LRRLRAC(doxorubicin)K(biotin) and 
G5-LRRLRAC(MMAF)K(biotin) in which G5-LRRLRACK(biotin) was used as a starting material.
Cyclization of linear peptide using native chemical ligation. Cyclization of the L-linear peptide 
precursor peptide was performed by conversion of the thiazolidine residue into a Cys residue and subse-
quent native chemical ligation (NCL), according to Supplementary Scheme 1. To convert the thiazolidine 
residue into a Cys residue, 30 mg peptide (2 mM) was dissolved in 0.2 M sodium phosphate buffer con-
taining 6 M guanidine·HCl, 20 mM TCEP·HCl, and 0.2 M methoxyamine hydrochloride (MeONH2·HCl). 
The reaction was incubated at pH 4.0 at RT for 6 h. In the same pot36, NCL was performed to cyclize 
the peptide by adding 10 mM 4-mercaptophenylacetic acid (MPAA) and incubating at pH 7.0 for 1 h at 
RT37. The cyclized product was purified by semi-preparative RP-HPLC. Pure fractions that were con-
firmed by MALDI and analytical RP-HPLC were combined and lyophilized to give 7 mg, 4.3 μ mol (26.1% 
yield). The Cys residue in the cyclized peptide was alkylated using 50 mM bromoacetamide and 20 mM 
TCEP·HCl in 0.2 M sodium phosphate buffer at pH 7.0 for 15 min at RT. Once complete, the reactions 
were quenched with 100 mM 2-mercaptoethanesulfonate (MESNa) and purified by semi-preparative 
RP-HPLC. Fractions containing the pure, alkylated L-cyclic peptide were combined and lyophilized to 
give 2.3 mg, 1.4 μ mol (31.7% yield). Cyclization of the D peptide was performed using the same method 
as described for the L cyclic peptide. The pure D cyclic peptide yield was 6.0 mg, 3.7 μ mol (19.1% yield) 
and the alkylated D cyclic peptide yield was 2.2 mg, 1.3 μ mol (35.4% yield).
Sortase-mediated ligation. Sortase A was used to ligate peptides containing the N-terminal oli-
goglycine motif to LFN-DTA-LPSTGG (LDn) as previously described. Staphylococcus aureus SrtA 
(P94S/D160N/K196T; SrtA*) evolved by Chen, et al. was used for our sortase-mediated ligations38. The 
purity of the ligated product was analyzed by LCMS. Concentrations of the ligated products containing 
non-canonical functionalities were determined using Bradford assay.
Protein synthesis inhibition assay. CHO-K1 cells were maintained in F-12K medium containing 
10% (v/v) fetal bovine serum, 100 U mL−1 penicillin and 100 μ g mL−1 streptomycin at 37 °C and 5% CO2. 
CHO-K1 (3.0 × 104 per well) were seeded into a 96-well plate and incubated overnight. The following 
day, the cells were treated with ten-fold serial dilutions of each construct (LDn1–11) in the presence of 
20 nM PA for 30 minutes at 37 °C and 5% CO2. After treatment, the cells were washed three times with 
PBS and then treated with 100 μ L leucine free medium containing 1 μ Ci mL−1 3H-Leucine (PerkinElmer) 
for 1 hour at 37 °C and 5% CO2. After treatment with 3H-Leu, the cells were washed three times with PBS 
and then suspended in 150 μ L of scintillation fluid. 3H-Leu incorporation was measured using a scintil-
lation counter to determine the inhibition of protein synthesis by LFN-DTA in the cytosol. Cells treated 
with PA only were used for normalization. Each experiment was done in triplicate. The data were plotted 
using Origin8 using Sigmoidal Boltzmann Fit using equation = + −
+
−y A2 A A
e
1 2
1
x x
dx
0
 and x0 represents the 
log(EC50) values.
Translocation of LDn1–11 and cytosolic and total cell lysate extraction. CHO-K1 (2.0 × 105 
per well) were seeded in a 12-well plate and incubated overnight. The cells were treated with 100 nM 
LDn1–11, LDn1-bio to LDn6-bio, LDn9-bio, and LDn11-bio in the presence of 20 nM PA for 12 hours 
at 37 °C and 5% CO2. After treatment, the cells were lifted and the cell surface was digested with 0.25% 
trypsin-EDTA for 5 minutes. The cells were then washed twice with PBS. For cytosolic protein extraction, 
0.5 × 105 cells were resuspended in 50 μ L of 50 μ g mL−1 digitonin in 75 mM NaCl, 1 mM NaH2PO4, 8 mM 
Na2HPO4, 250 mM sucrose supplemented with Roche protease inhibitor cocktail for 10 min on ice, and 
centrifuged for 5 minutes at 13,000 rpm. For total protein extraction, cells were lysed in total cell lysis 
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buffer (25 mM Tris, 150 mM NaCl, 1% v/v NP-40, pH 7.5) supplemented with Roche protease inhibitor 
cocktail on ice for 30 minutes and centrifuged for 10 minutes at 13,000 rpm. Both supernatants were 
collected for western blot.
Western blot of extracted material. Extracted material was run on an SDS-PAGE gel (Life 
Technologies) for 35 minutes at 165 V and then transferred onto a nitrocellulose membrane soaked in 
48 mM Tris, 39 mM glycine, 0.0375% SDS, 20% methanol and using a TE 70 Semi-Dry Transfer Unit 
(GE) for 1 hour at 17 V. The membrane was blocked at room temperature for 2 hours using LI-COR 
Odyssey blocking buffer (PBS). The membrane was immunostained overnight with anti-DTA, anti-LF, 
anti-Erk1/2, or anti-Rab5 in TBST at 4 °C. After incubation, the membrane was washed with TBST and 
incubated with the appropriate secondary antibody in TBST for 1 hour at room temperature then washed 
with TBST. The membrane was imaged by LI-COR Odyssey infrared imaging system.
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